nodes	percent_of_prediction	percent_of_DWPC	metapath
Framycetin—Steatorrhoea—Azathioprine—multiple sclerosis	0.0473	0.0926	CcSEcCtD
Framycetin—CXCR4—Binding and entry of HIV virion—CCR5—multiple sclerosis	0.0399	0.0947	CbGpPWpGaD
Framycetin—CXCR4—Binding and entry of HIV virion—CD4—multiple sclerosis	0.025	0.0595	CbGpPWpGaD
Framycetin—Posterior subcapsular cataract—Prednisolone—multiple sclerosis	0.0213	0.0416	CcSEcCtD
Framycetin—Posterior subcapsular cataract—Dexamethasone—multiple sclerosis	0.0178	0.0347	CcSEcCtD
Framycetin—Posterior subcapsular cataract—Betamethasone—multiple sclerosis	0.0178	0.0347	CcSEcCtD
Framycetin—Secondary infection—Azathioprine—multiple sclerosis	0.0169	0.033	CcSEcCtD
Framycetin—Nerve injury—Prednisolone—multiple sclerosis	0.0151	0.0295	CcSEcCtD
Framycetin—CXCR4—Early Phase of HIV Life Cycle—CCR5—multiple sclerosis	0.0146	0.0348	CbGpPWpGaD
Framycetin—Malabsorption—Methotrexate—multiple sclerosis	0.0138	0.027	CcSEcCtD
Framycetin—CXCR4—retina—multiple sclerosis	0.0135	0.199	CbGeAlD
Framycetin—Ulcerative keratitis—Prednisolone—multiple sclerosis	0.013	0.0255	CcSEcCtD
Framycetin—Cataract subcapsular—Prednisolone—multiple sclerosis	0.0126	0.0247	CcSEcCtD
Framycetin—Nerve injury—Dexamethasone—multiple sclerosis	0.0126	0.0246	CcSEcCtD
Framycetin—Nerve injury—Betamethasone—multiple sclerosis	0.0126	0.0246	CcSEcCtD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CXCL13—multiple sclerosis	0.0116	0.0276	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCR1—multiple sclerosis	0.0116	0.0276	CbGpPWpGaD
Framycetin—Cataract subcapsular—Triamcinolone—multiple sclerosis	0.0116	0.0227	CcSEcCtD
Framycetin—Cataract subcapsular—Methylprednisolone—multiple sclerosis	0.0116	0.0226	CcSEcCtD
Framycetin—Nerve injury—Prednisone—multiple sclerosis	0.011	0.0214	CcSEcCtD
Framycetin—Eye infection—Prednisolone—multiple sclerosis	0.0106	0.0208	CcSEcCtD
Framycetin—Cataract subcapsular—Dexamethasone—multiple sclerosis	0.0105	0.0206	CcSEcCtD
Framycetin—Cataract subcapsular—Betamethasone—multiple sclerosis	0.0105	0.0206	CcSEcCtD
Framycetin—Secondary infection—Triamcinolone—multiple sclerosis	0.0103	0.0202	CcSEcCtD
Framycetin—Secondary infection—Methylprednisolone—multiple sclerosis	0.0103	0.0201	CcSEcCtD
Framycetin—CXCR4—medulla oblongata—multiple sclerosis	0.00977	0.144	CbGeAlD
Framycetin—CXCR4—CXCR4-mediated signaling events—RGS1—multiple sclerosis	0.00969	0.023	CbGpPWpGaD
Framycetin—Ulcerative keratitis—Prednisone—multiple sclerosis	0.00947	0.0185	CcSEcCtD
Framycetin—Secondary infection—Betamethasone—multiple sclerosis	0.00935	0.0183	CcSEcCtD
Framycetin—Secondary infection—Dexamethasone—multiple sclerosis	0.00935	0.0183	CcSEcCtD
Framycetin—CXCR4—Peptide GPCRs—CCR1—multiple sclerosis	0.0093	0.0221	CbGpPWpGaD
Framycetin—CXCR4—Early Phase of HIV Life Cycle—CD4—multiple sclerosis	0.00919	0.0218	CbGpPWpGaD
Framycetin—Cataract subcapsular—Prednisone—multiple sclerosis	0.00917	0.0179	CcSEcCtD
Framycetin—CXCR4—midbrain—multiple sclerosis	0.00893	0.132	CbGeAlD
Framycetin—Eye infection—Betamethasone—multiple sclerosis	0.00887	0.0173	CcSEcCtD
Framycetin—Eye infection—Dexamethasone—multiple sclerosis	0.00887	0.0173	CcSEcCtD
Framycetin—CXCR4—spinal cord—multiple sclerosis	0.00871	0.128	CbGeAlD
Framycetin—CXCR4—Syndecan-4-mediated signaling events—CCL5—multiple sclerosis	0.00838	0.0199	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCL3—multiple sclerosis	0.00828	0.0197	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CXCR3—multiple sclerosis	0.0077	0.0183	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—HLA-DRA—multiple sclerosis	0.00765	0.0182	CbGpPWpGaD
Framycetin—Impaired healing—Prednisolone—multiple sclerosis	0.00762	0.0149	CcSEcCtD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCR2—multiple sclerosis	0.00749	0.0178	CbGpPWpGaD
Framycetin—CXCR4—nervous system—multiple sclerosis	0.00734	0.108	CbGeAlD
Framycetin—CXCR4—central nervous system—multiple sclerosis	0.00707	0.104	CbGeAlD
Framycetin—Impaired healing—Triamcinolone—multiple sclerosis	0.007	0.0137	CcSEcCtD
Framycetin—Nephropathy toxic—Mitoxantrone—multiple sclerosis	0.00699	0.0137	CcSEcCtD
Framycetin—Impaired healing—Methylprednisolone—multiple sclerosis	0.00699	0.0137	CcSEcCtD
Framycetin—CXCR4—cerebellum—multiple sclerosis	0.00691	0.102	CbGeAlD
Framycetin—Impaired healing—Betamethasone—multiple sclerosis	0.00635	0.0124	CcSEcCtD
Framycetin—Impaired healing—Dexamethasone—multiple sclerosis	0.00635	0.0124	CcSEcCtD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CXCL10—multiple sclerosis	0.00622	0.0148	CbGpPWpGaD
Framycetin—CXCR4—Peptide GPCRs—CXCR3—multiple sclerosis	0.00616	0.0146	CbGpPWpGaD
Framycetin—CXCR4—Peptide GPCRs—CCR2—multiple sclerosis	0.00599	0.0142	CbGpPWpGaD
Framycetin—CXCR4—brain—multiple sclerosis	0.00561	0.0827	CbGeAlD
Framycetin—Impaired healing—Prednisone—multiple sclerosis	0.00553	0.0108	CcSEcCtD
Framycetin—CXCR4—CXCR4-mediated signaling events—PTPRC—multiple sclerosis	0.00542	0.0129	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCL5—multiple sclerosis	0.00536	0.0127	CbGpPWpGaD
Framycetin—Swelling—Cladribine—multiple sclerosis	0.00503	0.00983	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.00501	0.0119	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCR5—multiple sclerosis	0.00483	0.0115	CbGpPWpGaD
Framycetin—Impaired healing—Methotrexate—multiple sclerosis	0.00463	0.00904	CcSEcCtD
Framycetin—Viral infection—Mitoxantrone—multiple sclerosis	0.00444	0.00869	CcSEcCtD
Framycetin—Glaucoma—Prednisolone—multiple sclerosis	0.00437	0.00855	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.00437	0.0104	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.00437	0.0104	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—RGS1—multiple sclerosis	0.00426	0.0101	CbGpPWpGaD
Framycetin—CXCR4—Syndecan-4-mediated signaling events—MMP9—multiple sclerosis	0.00413	0.00981	CbGpPWpGaD
Framycetin—CXCR4—S1P3 pathway—MAPK1—multiple sclerosis	0.00407	0.00966	CbGpPWpGaD
Framycetin—Glaucoma—Triamcinolone—multiple sclerosis	0.00402	0.00787	CcSEcCtD
Framycetin—Glaucoma—Methylprednisolone—multiple sclerosis	0.00401	0.00785	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.00398	0.00946	CbGpPWpGaD
Framycetin—CXCR4—Peptide GPCRs—CCR5—multiple sclerosis	0.00386	0.00918	CbGpPWpGaD
Framycetin—Infection—Fingolimod—multiple sclerosis	0.00382	0.00747	CcSEcCtD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.00374	0.0089	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCL2—multiple sclerosis	0.00369	0.00877	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.00369	0.00877	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CCR1—multiple sclerosis	0.00369	0.00877	CbGpPWpGaD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—IL1B—multiple sclerosis	0.00366	0.00871	CbGpPWpGaD
Framycetin—Glaucoma—Betamethasone—multiple sclerosis	0.00365	0.00714	CcSEcCtD
Framycetin—Glaucoma—Dexamethasone—multiple sclerosis	0.00365	0.00714	CcSEcCtD
Framycetin—Viral infection—Prednisolone—multiple sclerosis	0.00365	0.00713	CcSEcCtD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.00342	0.00814	CbGpPWpGaD
Framycetin—Swelling—Mitoxantrone—multiple sclerosis	0.0033	0.00646	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.00321	0.00762	CbGpPWpGaD
Framycetin—Glaucoma—Prednisone—multiple sclerosis	0.00318	0.00622	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.00312	0.00741	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—HLA-DRB1—multiple sclerosis	0.00311	0.00738	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—S1PR1—multiple sclerosis	0.00303	0.0072	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00293	0.00697	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00293	0.00697	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.0029	0.00689	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00282	0.0067	CbGpPWpGaD
Framycetin—Pruritus—Fingolimod—multiple sclerosis	0.00272	0.00532	CcSEcCtD
Framycetin—Erythema—Cladribine—multiple sclerosis	0.00267	0.00522	CcSEcCtD
Framycetin—Viral infection—Prednisone—multiple sclerosis	0.00265	0.00518	CcSEcCtD
Framycetin—Diarrhoea—Fingolimod—multiple sclerosis	0.00263	0.00514	CcSEcCtD
Framycetin—CXCR4—HIV Infection—CD28—multiple sclerosis	0.00259	0.00616	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.00244	0.00581	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—GPR65—multiple sclerosis	0.00244	0.00581	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CCR2—multiple sclerosis	0.00238	0.00565	CbGpPWpGaD
Framycetin—CXCR4—HIV Life Cycle—CCR5—multiple sclerosis	0.00237	0.00564	CbGpPWpGaD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00235	0.00558	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00234	0.00557	CbGpPWpGaD
Framycetin—CXCR4—Cardiac Progenitor Differentiation—TGFB1—multiple sclerosis	0.00227	0.0054	CbGpPWpGaD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00227	0.00539	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCR1—multiple sclerosis	0.00223	0.00531	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CXCL13—multiple sclerosis	0.00223	0.00531	CbGpPWpGaD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00221	0.00524	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00219	0.00521	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—CD4—multiple sclerosis	0.00219	0.00521	CbGpPWpGaD
Framycetin—Infection—Cladribine—multiple sclerosis	0.00216	0.00423	CcSEcCtD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—multiple sclerosis	0.00215	0.0051	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00209	0.00497	CbGpPWpGaD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00204	0.00484	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00202	0.00479	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00201	0.00478	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00198	0.0047	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00194	0.00462	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—MMP9—multiple sclerosis	0.00191	0.00453	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00189	0.00449	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.00182	0.00432	CbGpPWpGaD
Framycetin—Infection—Azathioprine—multiple sclerosis	0.00176	0.00344	CcSEcCtD
Framycetin—Erythema—Mitoxantrone—multiple sclerosis	0.00176	0.00343	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00174	0.00415	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00171	0.00407	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CCL5—multiple sclerosis	0.0017	0.00404	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—STAT3—multiple sclerosis	0.0017	0.00403	CbGpPWpGaD
Framycetin—CXCR4—HIV Infection—CCR5—multiple sclerosis	0.00164	0.0039	CbGpPWpGaD
Framycetin—Hypersensitivity—Cladribine—multiple sclerosis	0.00161	0.00314	CcSEcCtD
Framycetin—CXCR4—HIV Infection—HLA-A—multiple sclerosis	0.0016	0.0038	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCL3—multiple sclerosis	0.00159	0.00378	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00157	0.00373	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—S1PR1—multiple sclerosis	0.00156	0.0037	CbGpPWpGaD
Framycetin—Pruritus—Cladribine—multiple sclerosis	0.00154	0.00301	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—PTGER4—multiple sclerosis	0.00153	0.00364	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—CCR5—multiple sclerosis	0.00153	0.00364	CbGpPWpGaD
Framycetin—Diarrhoea—Cladribine—multiple sclerosis	0.00149	0.00292	CcSEcCtD
Framycetin—CXCR4—HIV Life Cycle—CD4—multiple sclerosis	0.00149	0.00354	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CXCR3—multiple sclerosis	0.00148	0.00352	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—RGS1—multiple sclerosis	0.00146	0.00346	CbGpPWpGaD
Framycetin—Erythema—Prednisolone—multiple sclerosis	0.00144	0.00282	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—CCR2—multiple sclerosis	0.00144	0.00342	CbGpPWpGaD
Framycetin—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.00143	0.0028	CcSEcCtD
Framycetin—Infection—Mitoxantrone—multiple sclerosis	0.00142	0.00278	CcSEcCtD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.00142	0.00338	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.00142	0.00337	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.00139	0.0033	CbGpPWpGaD
Framycetin—Vomiting—Cladribine—multiple sclerosis	0.00139	0.00271	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GPR65—multiple sclerosis	0.00138	0.00328	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.00135	0.00321	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CNR1—multiple sclerosis	0.00133	0.00316	CbGpPWpGaD
Framycetin—Erythema—Triamcinolone—multiple sclerosis	0.00132	0.00259	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—RGS1—multiple sclerosis	0.00132	0.00314	CbGpPWpGaD
Framycetin—Erythema—Methylprednisolone—multiple sclerosis	0.00132	0.00258	CcSEcCtD
Framycetin—Hypersensitivity—Azathioprine—multiple sclerosis	0.00131	0.00255	CcSEcCtD
Framycetin—Nausea—Cladribine—multiple sclerosis	0.00129	0.00253	CcSEcCtD
Framycetin—CXCR4—Disease—GPC5—multiple sclerosis	0.00128	0.00303	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00126	0.003	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CCR1—multiple sclerosis	0.00126	0.003	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GPR65—multiple sclerosis	0.00125	0.00298	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.00122	0.0029	CbGpPWpGaD
Framycetin—Diarrhoea—Azathioprine—multiple sclerosis	0.00121	0.00237	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—LINGO1—multiple sclerosis	0.00121	0.00288	CbGpPWpGaD
Framycetin—Erythema—Betamethasone—multiple sclerosis	0.0012	0.00235	CcSEcCtD
Framycetin—Erythema—Dexamethasone—multiple sclerosis	0.0012	0.00235	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—POMC—multiple sclerosis	0.0012	0.00285	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CXCL10—multiple sclerosis	0.0012	0.00284	CbGpPWpGaD
Framycetin—Anaphylactic shock—Prednisolone—multiple sclerosis	0.00118	0.0023	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CXCL13—multiple sclerosis	0.00115	0.00272	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCR1—multiple sclerosis	0.00115	0.00272	CbGpPWpGaD
Framycetin—Vomiting—Azathioprine—multiple sclerosis	0.00113	0.0022	CcSEcCtD
Framycetin—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.00108	0.00211	CcSEcCtD
Framycetin—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00108	0.00211	CcSEcCtD
Framycetin—Infection—Triamcinolone—multiple sclerosis	0.00107	0.0021	CcSEcCtD
Framycetin—Infection—Methylprednisolone—multiple sclerosis	0.00107	0.00209	CcSEcCtD
Framycetin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00106	0.00206	CcSEcCtD
Framycetin—Nausea—Azathioprine—multiple sclerosis	0.00105	0.00206	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—TAGAP—multiple sclerosis	0.00105	0.0025	CbGpPWpGaD
Framycetin—Erythema—Prednisone—multiple sclerosis	0.00105	0.00205	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—CCL5—multiple sclerosis	0.00103	0.00245	CbGpPWpGaD
Framycetin—CXCR4—HIV Infection—CD4—multiple sclerosis	0.00103	0.00245	CbGpPWpGaD
Framycetin—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000981	0.00192	CcSEcCtD
Framycetin—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000981	0.00192	CcSEcCtD
Framycetin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00098	0.00192	CcSEcCtD
Framycetin—Infection—Dexamethasone—multiple sclerosis	0.000974	0.0019	CcSEcCtD
Framycetin—Infection—Betamethasone—multiple sclerosis	0.000974	0.0019	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000952	0.00226	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000932	0.00221	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCR5—multiple sclerosis	0.000928	0.0022	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—S1PR1—multiple sclerosis	0.000919	0.00218	CbGpPWpGaD
Framycetin—Vomiting—Mitoxantrone—multiple sclerosis	0.000911	0.00178	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—GPC5—multiple sclerosis	0.000894	0.00212	CbGpPWpGaD
Framycetin—Erythema—Methotrexate—multiple sclerosis	0.000874	0.00171	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000866	0.00206	CbGpPWpGaD
Framycetin—Hypersensitivity—Prednisolone—multiple sclerosis	0.000866	0.00169	CcSEcCtD
Framycetin—Anaphylactic shock—Prednisone—multiple sclerosis	0.000854	0.00167	CcSEcCtD
Framycetin—Nausea—Mitoxantrone—multiple sclerosis	0.000851	0.00166	CcSEcCtD
Framycetin—Infection—Prednisone—multiple sclerosis	0.000848	0.00166	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000836	0.00199	CbGpPWpGaD
Framycetin—CXCR4—Disease—RPL5—multiple sclerosis	0.00083	0.00197	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCL3—multiple sclerosis	0.000817	0.00194	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CCR2—multiple sclerosis	0.000814	0.00193	CbGpPWpGaD
Framycetin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000796	0.00156	CcSEcCtD
Framycetin—CXCR4—Disease—SLC11A1—multiple sclerosis	0.000795	0.00189	CbGpPWpGaD
Framycetin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000794	0.00155	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—PTGER4—multiple sclerosis	0.000786	0.00187	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RGS1—multiple sclerosis	0.000781	0.00186	CbGpPWpGaD
Framycetin—Pruritus—Triamcinolone—multiple sclerosis	0.000765	0.0015	CcSEcCtD
Framycetin—Pruritus—Methylprednisolone—multiple sclerosis	0.000763	0.00149	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CXCR3—multiple sclerosis	0.00076	0.0018	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CNR1—multiple sclerosis	0.000751	0.00178	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GPR65—multiple sclerosis	0.000741	0.00176	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCR2—multiple sclerosis	0.000739	0.00176	CbGpPWpGaD
Framycetin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000738	0.00144	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—POMC—multiple sclerosis	0.000725	0.00172	CbGpPWpGaD
Framycetin—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000714	0.0014	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—CCL2—multiple sclerosis	0.000709	0.00169	CbGpPWpGaD
Framycetin—Infection—Methotrexate—multiple sclerosis	0.000709	0.00139	CcSEcCtD
Framycetin—Nausea—Prednisolone—multiple sclerosis	0.000698	0.00136	CcSEcCtD
Framycetin—Pruritus—Dexamethasone—multiple sclerosis	0.000694	0.00136	CcSEcCtD
Framycetin—Pruritus—Betamethasone—multiple sclerosis	0.000694	0.00136	CcSEcCtD
Framycetin—Vomiting—Triamcinolone—multiple sclerosis	0.000687	0.00134	CcSEcCtD
Framycetin—Vomiting—Methylprednisolone—multiple sclerosis	0.000686	0.00134	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CNR1—multiple sclerosis	0.000682	0.00162	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CXCL13—multiple sclerosis	0.000677	0.00161	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCR1—multiple sclerosis	0.000677	0.00161	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000676	0.00161	CbGpPWpGaD
Framycetin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000671	0.00131	CcSEcCtD
Framycetin—Diarrhoea—Betamethasone—multiple sclerosis	0.000671	0.00131	CcSEcCtD
Framycetin—Nausea—Triamcinolone—multiple sclerosis	0.000642	0.00126	CcSEcCtD
Framycetin—Nausea—Methylprednisolone—multiple sclerosis	0.00064	0.00125	CcSEcCtD
Framycetin—CXCR4—Disease—CD28—multiple sclerosis	0.000635	0.00151	CbGpPWpGaD
Framycetin—Hypersensitivity—Prednisone—multiple sclerosis	0.000629	0.00123	CcSEcCtD
Framycetin—Vomiting—Dexamethasone—multiple sclerosis	0.000623	0.00122	CcSEcCtD
Framycetin—Vomiting—Betamethasone—multiple sclerosis	0.000623	0.00122	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CXCL10—multiple sclerosis	0.000614	0.00146	CbGpPWpGaD
Framycetin—Pruritus—Prednisone—multiple sclerosis	0.000604	0.00118	CcSEcCtD
Framycetin—Diarrhoea—Prednisone—multiple sclerosis	0.000584	0.00114	CcSEcCtD
Framycetin—Nausea—Betamethasone—multiple sclerosis	0.000582	0.00114	CcSEcCtD
Framycetin—Nausea—Dexamethasone—multiple sclerosis	0.000582	0.00114	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CCL5—multiple sclerosis	0.000582	0.00138	CbGpPWpGaD
Framycetin—Vomiting—Prednisone—multiple sclerosis	0.000543	0.00106	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CCL5—multiple sclerosis	0.000528	0.00126	CbGpPWpGaD
Framycetin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000526	0.00103	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CCR5—multiple sclerosis	0.000524	0.00125	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000517	0.00123	CbGpPWpGaD
Framycetin—Nausea—Prednisone—multiple sclerosis	0.000507	0.000992	CcSEcCtD
Framycetin—Pruritus—Methotrexate—multiple sclerosis	0.000505	0.000987	CcSEcCtD
Framycetin—Diarrhoea—Methotrexate—multiple sclerosis	0.000488	0.000955	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—CCL3—multiple sclerosis	0.000483	0.00115	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCR5—multiple sclerosis	0.000476	0.00113	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL2RA—multiple sclerosis	0.000469	0.00112	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PTGER4—multiple sclerosis	0.000465	0.0011	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PGR—multiple sclerosis	0.000458	0.00109	CbGpPWpGaD
Framycetin—Vomiting—Methotrexate—multiple sclerosis	0.000454	0.000887	CcSEcCtD
Framycetin—CXCR4—Disease—CD86—multiple sclerosis	0.000453	0.00108	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CXCR3—multiple sclerosis	0.000449	0.00107	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CD28—multiple sclerosis	0.000444	0.00106	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCR2—multiple sclerosis	0.000436	0.00104	CbGpPWpGaD
Framycetin—Nausea—Methotrexate—multiple sclerosis	0.000424	0.000829	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—POMC—multiple sclerosis	0.00041	0.000974	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CNR1—multiple sclerosis	0.000403	0.000957	CbGpPWpGaD
Framycetin—CXCR4—Disease—CCR5—multiple sclerosis	0.000402	0.000954	CbGpPWpGaD
Framycetin—CXCR4—Disease—HLA-A—multiple sclerosis	0.000391	0.00093	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—POMC—multiple sclerosis	0.000372	0.000884	CbGpPWpGaD
Framycetin—CXCR4—Disease—APOE—multiple sclerosis	0.000365	0.000868	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCL2—multiple sclerosis	0.000364	0.000865	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CXCL10—multiple sclerosis	0.000363	0.000862	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—TYK2—multiple sclerosis	0.000331	0.000786	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD80—multiple sclerosis	0.00033	0.000785	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CD86—multiple sclerosis	0.000317	0.000754	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL5—multiple sclerosis	0.000312	0.000742	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—IL2—multiple sclerosis	0.000303	0.00072	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SPP1—multiple sclerosis	0.000289	0.000687	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCR5—multiple sclerosis	0.000281	0.000668	CbGpPWpGaD
Framycetin—CXCR4—Disease—TYK2—multiple sclerosis	0.000279	0.000663	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL2RA—multiple sclerosis	0.000277	0.000659	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL2—multiple sclerosis	0.000275	0.000654	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—APOE—multiple sclerosis	0.000256	0.000608	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD4—multiple sclerosis	0.000252	0.000599	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CD80—multiple sclerosis	0.000231	0.00055	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—POMC—multiple sclerosis	0.00022	0.000522	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL2—multiple sclerosis	0.000215	0.000511	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—MAPK1—multiple sclerosis	0.00021	0.0005	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TYK2—multiple sclerosis	0.000195	0.000464	CbGpPWpGaD
Framycetin—CXCR4—Disease—STAT3—multiple sclerosis	0.000195	0.000464	CbGpPWpGaD
Framycetin—CXCR4—Disease—MYC—multiple sclerosis	0.000181	0.000431	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFB1—multiple sclerosis	0.000181	0.00043	CbGpPWpGaD
Framycetin—CXCR4—Disease—MAPK1—multiple sclerosis	0.000178	0.000422	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL2—multiple sclerosis	0.000163	0.000386	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL6—multiple sclerosis	0.000162	0.000384	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MMP9—multiple sclerosis	0.000154	0.000365	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—STAT3—multiple sclerosis	0.000137	0.000325	CbGpPWpGaD
Framycetin—CXCR4—Disease—IL6—multiple sclerosis	0.000136	0.000324	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MYC—multiple sclerosis	0.000127	0.000302	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TGFB1—multiple sclerosis	0.000127	0.000301	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MAPK1—multiple sclerosis	0.000124	0.000295	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL6—multiple sclerosis	9.55e-05	0.000227	CbGpPWpGaD
